All News

Tava’s network of therapists will be added to Health Advocate’s existing network.

The latest news for pharma industry insiders.

Users will be able to access DeepScribe’s documentation platform through AWS.

The latest news for pharma industry insiders.

The program is designed to tackle issues related to the high cost of prescription medication.

Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.

The takeover is contingent upon a minimum acceptance rate of 65% and other conditions outlined in the offer document.

The latest news for pharma industry insiders.

This facility is the first of four facilities to be built in the area.

Treatment was initially approved in 2017 for the same indication in children aged 12 and up.

Joint venture aims to implement Invenra’s B-Body bispecific antibody platform to enhance Astellas' research and development efforts.

Decree comes amid the FDA’s 2021 inspection of Philips’ Murrysville facility and the subsequent voluntary recall of its sleep and respiratory care devices.

The vaccine is already approved for older adults.

The move is part of Synaptogenix’s partnership with Cannasoul.

A Harvard Business School Healthcare Alumni Association Q&A with Louis Kassa, CEO of the Pennsylvania Biotechnology Center.

The latest news for pharma industry insiders.

The pharmacy will now operate as Saveway Compounding Pharmacy, a Myonex company.

Collaboration aims to advance the development of treatments for multiple neurodegenerative conditions, including amyotrophic lateral sclerosis.

A combination of data from the EMERGENT-4 trial and pooled data from the EMERGENT program showed the promise of KarXT (xanomeline-trospium) in providing symptom improvement for people with schizophrenia.

These expansions include a new product, along with improvements to existing products.

The latest news for pharma industry insiders.

Dovato is the first oral, two-drug, single-tablet regimen approved for patients 12 years of age and older who are living with HIV-1.

According to the letter, the FDA believes that the investigational apomorphine infusion device is not ready for approval in its current form.

PIONEER AF-PCI exploratory trial found that elderly patients experienced a lower rate of clinically significant bleeding after 12 months of treatment with Xarelto (rivaroxaban).

The approval of AstraZeneca’s and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) for adults with unresectable or metastatic HER2-positive solid tumors adds to the drug's approved indications in breast cancer, non-small cell lung cancer, and gastroesophageal junction adenocarcinoma.

The latest news for pharma industry insiders.

The deal, which is worth approximately $13.1 billion, is part of J&J MedTech's goal to expand into high-growth markets.

Decision to discontinue marketing authorizations for Relyvrio/Albrioza comes as a result of topline results from the Phase III PHOENIX trial in patients with amyotrophic lateral sclerosis.